Eric Venker, President & Immunovant CEO at Roivant Sciences Ltd. (ROIV), sold 275,000 shares at $22.45 ($6.2M) on 2025-12-23, disclosed to the SEC on 2025-12-29.
Seasonal sale ($6.2M) by President & Immunovant CEO — this insider has traded ROIV in December in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $22.45 | 200,000 | $4.5M | 72.7% |
| 2 | $22.53 | 75,000 | $1.7M | 27.3% |
| Total | $22.47 avg | 275,000 | $6.2M | 100% |
| Filing → |
| ROIV | SELL | 2026-09-01 | $7.2M | — | Filing → |
| ROIV | SELL | 2026-07-29 | $7.0M | — | Filing → |
| IMVT | SELL | 2026-07-06 | $119K | — | Filing → |